Skip to main content
Top
Published in: Virology Journal 1/2013

Open Access 01-12-2013 | Short report

Gene delivery in a mouse xenograft of a retargeted retrovirus to a solid 143B osteosarcoma

Authors: Xia Zhang, Anindita Sarangi, Dai-Tze Wu, Jaya Kanduri, Monica J Roth

Published in: Virology Journal | Issue 1/2013

Login to get access

Abstract

Background

Osteosarcomas are the most common primary bone malignancies found in children and adolescents. An optimized system was developed for efficient retroviral gene delivery into solid 143B osteosarcoma tumors in mice using a retargeted Env. In these studies, the viral Env CP was isolated from an in vitro screen of a library of feline leukemia virus Env randomized in the receptor-binding domain and maintained high titer on human 143B osteosarcoma cell line.

Findings

The vector developed to express the random Env libraries encoded the drug selectable marker neo. To adapt this for studies in live animals, the murine based vector was modified to express the luciferase gene. The bicistronic vector developed expressed both the CP Env and luciferase in the presence of either the MPMV CTE or a WPRE element. Virus bearing the CP FeLV Env variant maintained high titers after concentration allowing for direct visualization of delivery of the luciferase gene in subcutaneous 143B osteosarcoma tumors.

Conclusion

This system serves as a proof-of-concept for the use of novel FeLV Env pseudotyped MLV particles for in vivo gene delivery. Gene delivery and expression of lucerifase from viral particles bearing the CP Env was readily detected in live mice after a single round of intratumor injection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Osborne T, Khanna C: A review of the association between osteosarcoma metastasis and protein translation. J Comparative Pathology 2012, 146: 132-142. 10.1016/j.jcpa.2011.12.007CrossRef Osborne T, Khanna C: A review of the association between osteosarcoma metastasis and protein translation. J Comparative Pathology 2012, 146: 132-142. 10.1016/j.jcpa.2011.12.007CrossRef
2.
go back to reference Krishnan K, Khanna C, Helman L: The biology of metastases in pediatric sarcomas. Cancer J 2005, 11: 306-313. 10.1097/00130404-200507000-00006PubMedCrossRef Krishnan K, Khanna C, Helman L: The biology of metastases in pediatric sarcomas. Cancer J 2005, 11: 306-313. 10.1097/00130404-200507000-00006PubMedCrossRef
3.
go back to reference Ferguson W, Goorin A: Current treatment of osteosarcoma. Cancer Invest 2001, 19: 292-315. 10.1081/CNV-100102557PubMedCrossRef Ferguson W, Goorin A: Current treatment of osteosarcoma. Cancer Invest 2001, 19: 292-315. 10.1081/CNV-100102557PubMedCrossRef
4.
go back to reference Ko S-C, Cheon J, Kao C, Gotoh A, Shirakawa T, Sikes RA, Karsenty G, Chung LWK: Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res 1996, 56: 4614-4619.PubMed Ko S-C, Cheon J, Kao C, Gotoh A, Shirakawa T, Sikes RA, Karsenty G, Chung LWK: Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res 1996, 56: 4614-4619.PubMed
5.
go back to reference Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P: Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol 2007, 25: 2057-2062. 10.1200/JCO.2006.07.7776PubMedCrossRef Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P: Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol 2007, 25: 2057-2062. 10.1200/JCO.2006.07.7776PubMedCrossRef
6.
go back to reference Meyers PA: Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 2009, 9: 1035-1049. 10.1586/era.09.69PubMedCrossRef Meyers PA: Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 2009, 9: 1035-1049. 10.1586/era.09.69PubMedCrossRef
7.
go back to reference Guo Y, Rubin E, Xie J, Zi X, Hoang B: Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res 2008, 466: 2039-2045. 10.1007/s11999-008-0344-yPubMedPubMedCentralCrossRef Guo Y, Rubin E, Xie J, Zi X, Hoang B: Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res 2008, 466: 2039-2045. 10.1007/s11999-008-0344-yPubMedPubMedCentralCrossRef
8.
go back to reference Su Y, Wagner E, Luo Q, Huang J, Chen L, He B, Zuo G, Shi Q, Zhang B, Zhu G, et al.: Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma. Oncogene 2011, 30: 3907-3917. 10.1038/onc.2011.97PubMedCrossRef Su Y, Wagner E, Luo Q, Huang J, Chen L, He B, Zuo G, Shi Q, Zhang B, Zhu G, et al.: Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma. Oncogene 2011, 30: 3907-3917. 10.1038/onc.2011.97PubMedCrossRef
9.
10.
go back to reference Bupp K, Roth MJ: Altering retroviral tropism using a random-display envelope library. Mol Ther 2002, 5: 329-335. 10.1006/mthe.2002.0546PubMedCrossRef Bupp K, Roth MJ: Altering retroviral tropism using a random-display envelope library. Mol Ther 2002, 5: 329-335. 10.1006/mthe.2002.0546PubMedCrossRef
11.
go back to reference Bupp K, Roth MJ: Targeting a retroviral vector in the absence of a known cell-targeting ligand. Hum Gene Ther 2003, 14: 1557-1564. 10.1089/104303403322495061PubMedCrossRef Bupp K, Roth MJ: Targeting a retroviral vector in the absence of a known cell-targeting ligand. Hum Gene Ther 2003, 14: 1557-1564. 10.1089/104303403322495061PubMedCrossRef
12.
go back to reference Mazari PM, Linder-Basso D, Sarangi A, Chang Y, Roth MJ: Single-round selection yields a unique retroviral envelope utilizing GPR172A as its host receptor. Proc Natl Acad Sci USA 2009, 106: 5848-5853. 10.1073/pnas.0809741106PubMedPubMedCentralCrossRef Mazari PM, Linder-Basso D, Sarangi A, Chang Y, Roth MJ: Single-round selection yields a unique retroviral envelope utilizing GPR172A as its host receptor. Proc Natl Acad Sci USA 2009, 106: 5848-5853. 10.1073/pnas.0809741106PubMedPubMedCentralCrossRef
13.
go back to reference Mazari PM, Argaw T, Valdivieso L, Zhang X, Marcucci KT, Salomon DR, Wilson CA, Roth MJ: Comparison of the convergent receptor utilization of a retargeted feline leukemia virus envelope with a naturally-occurring porcine endogenous retrovirus A. Virology 2012, 427: 118-126. 10.1016/j.virol.2012.02.012PubMedPubMedCentralCrossRef Mazari PM, Argaw T, Valdivieso L, Zhang X, Marcucci KT, Salomon DR, Wilson CA, Roth MJ: Comparison of the convergent receptor utilization of a retargeted feline leukemia virus envelope with a naturally-occurring porcine endogenous retrovirus A. Virology 2012, 427: 118-126. 10.1016/j.virol.2012.02.012PubMedPubMedCentralCrossRef
14.
go back to reference Goldman SJ, Chen E, Taylor R, Zhang S, Petrosky W, Reiss M, Jin S: Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice. PLoS One 2011, 6: e18269. 10.1371/journal.pone.0018269PubMedPubMedCentralCrossRef Goldman SJ, Chen E, Taylor R, Zhang S, Petrosky W, Reiss M, Jin S: Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice. PLoS One 2011, 6: e18269. 10.1371/journal.pone.0018269PubMedPubMedCentralCrossRef
15.
go back to reference Donello J, Loeb J, Hope T: Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998, 72: 5085-5092.PubMedPubMedCentral Donello J, Loeb J, Hope T: Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998, 72: 5085-5092.PubMedPubMedCentral
16.
go back to reference Zufferey R, Donello J, Trono D, Hope T: Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999, 73: 2886-2892.PubMedPubMedCentral Zufferey R, Donello J, Trono D, Hope T: Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999, 73: 2886-2892.PubMedPubMedCentral
17.
go back to reference Bray M, Prasad S, Dubay JW, Hunter E, Jeang KT, Rekosh D, Hammarskjold ML: A small element from the Mason- Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci USA 1994, 91: 1256-1260. 10.1073/pnas.91.4.1256PubMedPubMedCentralCrossRef Bray M, Prasad S, Dubay JW, Hunter E, Jeang KT, Rekosh D, Hammarskjold ML: A small element from the Mason- Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci USA 1994, 91: 1256-1260. 10.1073/pnas.91.4.1256PubMedPubMedCentralCrossRef
18.
go back to reference Pambalk K, Hohenadl C, Salmons B, Gunzburg WH, Renner M: Specific packaging of spliced retroviral vector transcripts lacking the Psi-region. Biochem Biophys Res Commun 2002, 293: 239-246. 10.1016/S0006-291X(02)00207-3PubMedCrossRef Pambalk K, Hohenadl C, Salmons B, Gunzburg WH, Renner M: Specific packaging of spliced retroviral vector transcripts lacking the Psi-region. Biochem Biophys Res Commun 2002, 293: 239-246. 10.1016/S0006-291X(02)00207-3PubMedCrossRef
19.
go back to reference Wu D-T, Aiyer S, Villanueva RA, Roth MJ: Development of an ELISA assay based on the murine leukemia virus p30 Capsid protein. J Virol Methods 2013. in press Wu D-T, Aiyer S, Villanueva RA, Roth MJ: Development of an ELISA assay based on the murine leukemia virus p30 Capsid protein. J Virol Methods 2013. in press
20.
go back to reference Luu H, Kang Q, Park J, Si W, Luo Q, Jiang W, Yin H, Montag A, Simon M, Peabody T, et al.: An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 2005, 22: 319-329. 10.1007/s10585-005-0365-9PubMedCrossRef Luu H, Kang Q, Park J, Si W, Luo Q, Jiang W, Yin H, Montag A, Simon M, Peabody T, et al.: An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 2005, 22: 319-329. 10.1007/s10585-005-0365-9PubMedCrossRef
21.
go back to reference Aurélie A, Albertini V, Baquero E, Ferlin A, Gaudin Y: Molecular and cellular aspects of Rhabdovirus entry. Viruses 2012, 4: 117-139. 10.3390/v4010117CrossRef Aurélie A, Albertini V, Baquero E, Ferlin A, Gaudin Y: Molecular and cellular aspects of Rhabdovirus entry. Viruses 2012, 4: 117-139. 10.3390/v4010117CrossRef
22.
go back to reference Logg CR, Baranick BT, Lemp NA, Kasahara N: Adaptive evolution of a tagged chimeric gammaretrovirus: identification of novel cis-acting elements that modulate splicing. J Mol Biol 2007, 369: 1214-1229. 10.1016/j.jmb.2007.04.026PubMedPubMedCentralCrossRef Logg CR, Baranick BT, Lemp NA, Kasahara N: Adaptive evolution of a tagged chimeric gammaretrovirus: identification of novel cis-acting elements that modulate splicing. J Mol Biol 2007, 369: 1214-1229. 10.1016/j.jmb.2007.04.026PubMedPubMedCentralCrossRef
Metadata
Title
Gene delivery in a mouse xenograft of a retargeted retrovirus to a solid 143B osteosarcoma
Authors
Xia Zhang
Anindita Sarangi
Dai-Tze Wu
Jaya Kanduri
Monica J Roth
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2013
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-10-194

Other articles of this Issue 1/2013

Virology Journal 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine